Partnering is central to Oasmia’s strategy, demonstrated by our global licensing agreement for our lead cancer therapy Apealea® (paclitaxel micellar) to a partner company. We are committed to building collaborations leveraging our expertise in research and development of novel and existing therapies, including our proprietary drug delivery platforms XR-17™ and XR-19.

We are actively seeking opportunities to acquire and develop novel product opportunities in areas of significant medical need. Oasmia welcomes opportunities to license commercialization rights and to collaborate with global pharmaceutical companies, regional partners and other stakeholders to help accelerate the availability of product candidates to patients in need.